Top

Published in:

01-11-2011 | Invited commentary

Struggling with subtypes: trying to bridge the gap between molecular breast cancer subtypes and clinical management

Author: Nadia Harbeck

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Excerpt

Modern understanding of breast cancer as a disease has undisputedly left the “Halstedian” worldview and has entered the molecular age. Formerly, breast cancer heterogeneity was defined simply by measurable differences such as nodal involvement or tumor size and subsequently by steroid hormone receptor positivity. Yet, the groundbreaking discoveries of Perou et al. [1] have taught us that there are distinct molecular subtypes of breast cancer that even carry clinical relevance with regard to patient outcome [2]. The fact that these subtypes and their clinical impact on breast cancer outcome can be consistently identified across data sets strongly suggests that they are indeed indicative of distinct intrinsic biological properties and behavior [3]. …

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874PubMedCrossRef

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418–8423 Epub 2003 Jun 26PubMedCrossRef

de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S (2010) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119(1):119–126PubMedCrossRef

Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Børresen-Dale AL (2006) Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7:127PubMedCrossRef

Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25(10):1239–1246 (Erratum in: J Clin Oncol 25(24):3790)PubMedCrossRef

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750PubMedCrossRef

Karn T, Ruckhäberle E, Hanker L, Müller V, Schmidt M, Solbach C, Gätje R, Gehrmann M, Holtrich U, Kaufmann M, Rody A (2011) Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat. doi:10.1007/s10549-010-1333-x

Bellizzi A, Malfettone A, Cardone RA, Mangia A (2010) NHERF1/EBP50 in breast cancer: clinical perspectives. Breast Care (Basel) 5(2):86–90CrossRef

10.

Mangia A, Chiriatti A, Bellizzi A, Malfettone A, Stea B, Zito FA, Reshkin SJ, Simone G, Paradiso A (2009) Biological role of NHERF1 protein expression in breast cancer. Histopathology 55(5):600–608PubMedCrossRef

11.

Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16(21):5222–5232PubMedCrossRef

12.

Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M, for the German Chemo N0 Study Group (2001) Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type I. J Natl Cancer Inst 93(12):913–920PubMedCrossRef

13.

Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Jänicke F, Thomssen C, Look MP, Foekens JA (2004) Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5(5):348–352PubMedCrossRef

14.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826PubMedCrossRef

15.

van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536PubMedCrossRef

16.

Weinman EJ, Hall RA, Friedman PA, Liu-Chen LY, Shenolikar S (2006) The association of NHERF adaptor proteins with g protein-coupled receptors and receptor tyrosine kinases. Annu Rev Physiol 68:491–505 ReviewPubMedCrossRef

17.

Cummings MC, Chambers R, Simpson PT, Lakhani SR (2011) Molecular classification of breast cancer: is it time to pack up our microscopes? Pathology 43(1):1–8PubMedCrossRef

18.

Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, Perou CM (2011) Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics 4:3PubMedCrossRef

Title: Struggling with subtypes: trying to bridge the gap between molecular breast cancer subtypes and clinical management
Author: Nadia Harbeck
Publication date: 01-11-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1489-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2011

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy

Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case–control study

A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients

Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer

Association between polymorphisms of the renin–angiotensin system genes and breast cancer risk: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer